CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO
Cannabis Use Doubles Among U.S Adults, Study Shows
An October 21, 2015, article published on the National Institutes of Health’s (NIH) website highlights the results of a study showing that the percentage of Americans who had used Cannabis within the last year had doubled over the last decade (4.1% in 2001-02 compared to 9.5% in 2012-2013). The survey results also show that the prevalence of Cannabis use disorder rose from 1.5 percent to 2.9 percent over the same time period (Prevalence of Marijuana Use Among U.S. Adults Doubles Over Past Decade). The study appears in the October 21st issue of JAMA Psychiatry and was conducted by researchers from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of NIH.
The Cannabis use data came from 79,000 people who were interviewed on alcohol use, drug use and related psychiatric conditions during the 2001-2002 and 2012-2013 surveys. An examination of the data by age and race revealed that young adults (ages 18 - 29) and African American and Hispanic individuals were at the highest risk for Cannabis use and Cannabis use disorder.
The article hints that the increase in the number of Americans who have used Cannabis may be attributable to changes in legal status and cultural attitudes toward Cannabis use in the United States. The authors note that this research underscores the need to provide information on the health and safety risks of Cannabis use such as drugged driving and Cannabis addiction.
Cerilliant offers a broad range of cannabinoid solution-based Certified Reference Materials (CRMs) including traditional cannabinoids routinely analyzed by MS methods in clinical toxicology, urine drug testing, and forensic analysis applications as well as their hydroxy, carboxy, and glucuronide metabolites and stable-labeled internal standards. Cerilliant also offers a wide selection of Cannabis testing cannabinoid solution CRMs for use in Cannabis potency testing and impurity profiling and pharmaceutical research.
Cerilliant provides its certified solution standards of Schedule I cannabinoids in a US DEA and Health Canada (with TK #’s)-exempt solution format, allowing laboratories to place orders without additional regulatory paperwork. These reference solutions are produced and certified to the highest industry standards including ISO Guide 34 and ISO/IEC 17025 and are classified as "Certified Reference Materials" in accordance with ISO requirements.

Return to Article List

© 2023 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany
Products | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact